financetom
Business
financetom
/
Business
/
JLL Q3 revenue up 10%, beats expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
JLL Q3 revenue up 10%, beats expectations
Nov 5, 2025 5:08 AM

(Corrects company name in headline)

Overview

* JLL Q3 revenue grows 10% yr/yr, beating analyst

expectations

* Adjusted EPS for Q3 beats consensus, rising 29% yr/yr

* Company repurchased $70 mln in shares this quarter, up

118%

yr/yr

Outlook

* JLL raises mid-point of full-year Adjusted EBITDA target

* Company expects continued momentum into the fourth quarter

* JLL sees alignment of data, tech, and AI as growth drivers

Result Drivers

* TRANSACTIONAL REVENUE - Growth driven by Capital Markets

Services, with strong performance in investment sales, debt

advisory, and equity advisory

* RESILIENT REVENUE - Growth in Project Management and

Workplace

Management within Real Estate Management Services

* TECHNOLOGY AND AI - Strategic focus on data, technology,

and AI

capabilities supports long-term growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $6.51 $6.48

Revenue bln bln (7

Analysts

)

Q3 Beat $4.50 $4.23 (9

Adjusted Analysts

EPS )

Q3 EPS $4.61

Q3 Beat $217.40 $207.56

Adjusted mln mln (6

Net Analysts

Income )

Q3 Beat $347.30 $345.96

Adjusted mln mln (9

EBITDA Analysts

)

Q3 Free $567.60

Cash mln

Flow

Analyst Coverage

* The current average analyst rating on the shares is "buy"

and

the breakdown of recommendations is 8 "strong buy" or "buy", 3

"hold" and no "sell" or "strong sell"

* Wall Street's median 12-month price target for Jones Lang

LaSalle Inc ( JLL ) is $359.00, about 16.7% above its November 4 closing

price of $299.04

* The stock recently traded at 15 times the next 12-month

earnings

vs. a P/E of 15 three months ago

Press Release:

For questions concerning the data in this report, contact

[email protected]. For any other questions or feedback,

contact .

(This story was created using Reuters automation and AI based

on LSEG and company data. It was checked and edited by a Reuters

journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Chemicals maker AdvanSix's Q2 sales fall 10%
Chemicals maker AdvanSix's Q2 sales fall 10%
Aug 1, 2025
Overview * AdvanSix ( ASIX ) Q2 sales fall 10% yr/yr to $410 mln, driven by softer demand * Adjusted EPS for Q2 at $1.24, down from $1.55 last year * Company claimed $8 mln in 45Q carbon capture tax credits in Q2 Outlook * AdvanSix ( ASIX ) anticipates higher ammonium sulfate pricing in 3Q25 year-over-year * Company expects...
Ares Management Q2 Earnings, Revenue Rise
Ares Management Q2 Earnings, Revenue Rise
Aug 1, 2025
06:39 AM EDT, 08/01/2025 (MT Newswires) -- Ares Management ( ARES ) reported Q2 after-tax realized income Friday of $1.03 per share, up from $0.99 a year earlier. Analysts polled by FactSet expected $1.08. Revenue for the quarter ended June 30 was $1.35 billion, compared with $788.7 million a year earlier. Four analysts surveyed by FactSet expected $1.01 billion. The...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
US plans Medicare, Medicaid coverage for weight-loss drugs, Washington Post reports
US plans Medicare, Medicaid coverage for weight-loss drugs, Washington Post reports
Aug 1, 2025
Aug 1 (Reuters) - The Trump administration is planning an experiment to cover weight-loss drugs under Medicare and Medicaid, the Washington Post reported on Friday, citing documents from the Centers for Medicare and Medicaid Services. GLP-1 drugs, originally developed for type 2 diabetes, have gained popularity for their ability to reduce body weight by suppressing appetite and slowing digestion. But...
Copyright 2023-2026 - www.financetom.com All Rights Reserved